

Policy Number	SUR701.018
Policy Effective Date	11/15/2024

Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas, or Bone

Table of Contents
Coverage
Policy Guidelines
Description
Rationale
Coding
References
Policy History

Related Policies (if applicable)
SUR701.032: Cryosurgical Ablation of Primary or Metastatic Liver Tumors
SUR717.004: Cryosurgical Ablation of the Prostate

Disclaimer

Carefully check state regulations and/or the member contract.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. **If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.**

Coverage

Cryosurgical ablation (cryoablation or cryosurgery) **may be considered medically necessary** for the treatment of breast fibroadenoma when **ALL** of the following criteria have been met:

- The lesion is sonographically visible; **AND**
- The diagnosis is histologically confirmed; **AND**
- The lesion is less than 2.5 cm in its largest diameter.

Cryosurgical ablation (cryoablation or cryosurgery), whether open, percutaneous or laparoscopic, **may be considered medically necessary** to treat localized renal cell carcinoma (RCC) that is no more than 4 cm in size when determined to be indicated by the treating physician for:

- Palliative treatment of medically or surgically inoperable tumor(s); **OR**
- Individuals for whom preservation of kidney function is necessary (i.e., the individual has one kidney or renal insufficiency defined by a glomerular filtration rate [GFR] of less than 60

mL/min per m²) and standard surgical approach (i.e., resection of renal tissue) is likely to substantially worsen kidney function; **OR**

- Individuals who have failed, or are a poor candidate for, standard treatment such as surgical intervention, radiation, chemotherapy, or opioids.

Cryosurgical ablation (cryoablation or cryosurgery), whether open, percutaneous or laparoscopic, **may be considered medically necessary** to treat lung cancer when **EITHER** of the following criteria is met:

- The individual has early-stage non-small cell lung cancer **and** is a poor candidate for surgery; **OR**
- The individual requires palliation for a central airway obstructing lesion.

Palliative cryoablation **may be medically necessary** for intractable pain due to bone metastasis.

Cryosurgical ablation (cryoablation or cryosurgery), whether open, percutaneous or laparoscopic, is **considered experimental, investigational and/or unproven** for **ALL** of the following:

- Treatments of all other types of breast tumors (including localized breast lesions) except as noted above; **OR**
- Pancreatic cancer; **OR**
- Lung cancer that does not meet the above criteria; **OR**
- Bone lesions (other than palliative care); **OR**
- Renal cell carcinoma (RCC) that does not meet the above criteria.

Policy Guidelines

None.

Description

Cryosurgical ablation (hereafter referred to as cryosurgery or cryoablation) involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound (US) guidance.

Renal Tumors

Localized kidney cancer is treated with radical nephrectomy or nephron-sparing surgery. Prognosis drops precipitously if the tumor extends outside the kidney capsule because chemotherapy is relatively ineffective against metastatic renal cell carcinoma.

Lung Tumors and Lung Metastases

Early-stage lung tumors are typically treated surgically. Patients with early-stage lung cancer who are not surgical candidates may be candidates for radiotherapy with curative intent.

Cryoablation is being investigated in patients who are medically inoperable, with small primary lung cancers or lung metastases from metastases from extrapulmonary primaries. Patients with more advanced local disease or metastatic disease may undergo chemotherapy with radiation following resection. Treatment is rarely curative; rather, it seeks to retard tumor growth or palliate symptoms.

Breast Tumors

Early-stage primary breast cancers are treated surgically. The selection of lumpectomy, modified radical mastectomy, or another approach is balanced against the patient's desire for breast conservation, the need for tumor-free margins in resected tissue, and the patient's age, hormone receptor status, and other factors. Adjuvant radiotherapy decreases local recurrences, particularly for those who select lumpectomy. Adjuvant hormonal therapy and/or chemotherapy are added, depending on presence and number of involved nodes, hormone receptor status, and other factors. Treatment of metastatic disease includes surgery to remove the lesion and combination chemotherapy.

Fibroadenomas are common benign tumors of the breast that can present as a palpable mass or a mammographic abnormality. These benign tumors are frequently surgically excised to rule out a malignancy.

Pancreatic Cancer

Pancreatic cancer is a relatively rare solid tumor that occurs almost exclusively in adults, and it is largely considered incurable. Surgical resection of tumors contained entirely within the pancreas is currently the only potentially curative treatment. However, the nature of the cancer is such that few tumors are found at such an early and potentially curable stage. Patients with more advanced local disease or metastatic disease may undergo chemotherapy with radiation following resection. Treatment is focused on slowing tumor growth and palliation of symptoms.

Bone Cancer and Bone Metastases

Primary bone cancers are extremely rare, accounting for less than 0.2% of all cancers. Bone metastases are more common, with clinical complications including debilitating bone pain. Treatment for bone metastases is performed to relieve local bone pain, provide stabilization, and prevent impending fracture or spinal cord compression.

Regulatory Status

Several cryoablation devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, proctology, thoracic surgery and ear, nose, and throat. Examples include, but are not limited to:

- Cryocare[®] Surgical System (Endocare);
- CryoGen Cryosurgical System (Cryosurgical);
- CryoHit[®] (Galil Medical) for the treatment of breast fibroadenoma;
- IceSense3[™], ProSense[™], and MultiSense Systems (IceCure Medical);

- SeedNet™ System (Galil Medical); and
- Visica® System (Sanarus Medical).

FDA Product Code: GEH.

Rationale

Medical policies assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Cryoablation for Early-Stage Kidney Cancer

Clinical Context and Therapy Purpose

The purpose of cryoablation in individuals who have early-stage kidney cancer is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with early-stage kidney tumors.

The policy addresses the use of cryoablation in 2 populations of patients who have early-stage renal cancer:

1. Patients who are candidates for surgery;
2. Patients who are not surgical candidates. Patients with 1 kidney or with renal insufficiency are likely to be deemed poor surgical candidates because a standard surgical approach (i.e., resection of renal tissue) is likely to worsen kidney function substantially.

Interventions

The therapy being considered is cryoablation, also referred to as cryosurgery.

Cryoablation involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Comparators

For patients with stage 1 kidney cancer who are surgical candidates, the comparator of interest is surgical resection. Surgery by partial nephrectomy, whenever feasible, or by radical nephrectomy is the standard of care for stage 1 kidney cancer.

For select patients, including those with small renal masses <2 cm or significant competing risks of death or morbidity from intervention, active surveillance is an option. Active surveillance entails serial abdominal imaging and periodic metastatic survey including blood work and chest imaging.

Outcomes

The general outcomes of interest are overall survival (OS), disease-specific survival, quality of life, and treatment-related morbidity.

The hypothesized advantages of cryosurgery include improved local control and benefits common to any minimally invasive procedure (e.g., preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization). For patients who are not surgical candidates due to renal insufficiency or who have 1 kidney, preservation of renal function is important.

Potential complications of cryosurgery include those caused by hypothermic damage to normal tissue adjacent to the tumor, structural damage along the probe track, and secondary tumors if cancerous cells are seeded during probe removal.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that captured longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Patients Who are Surgical Candidates

Randomized Controlled Trials

There are no RCTs of cryoablation compared to surgery for kidney cancer that were identified.

Systematic Reviews

Multiple systematic reviews of comparative observational studies have compared cryoablation to partial nephrectomy in patients with early kidney cancer. This section summarizes the most recent, relevant, and comprehensive reviews and meta-analyses, reported by Yanagisawa et al. (2022) (1), Uhlig et al. (2019) (2), Klatter et al. (2014) (3), and Tang et al. (2014) (4). Included studies and characteristics of the systematic reviews are described in Tables 1 and 2. The Yanagisawa et al (2022) review includes multiple types of ablation therapies (radiofrequency ablation [RFA], cryoablation, and microwave ablation) - only studies that focus on cryoablation are listed in Table 1.

Table 1. Cryoablation Studies Included in Systematic Reviews and Meta-Analyses Comparing Cryoablation to Partial Nephrectomy

Study	Yanagisawa et al. (2022) (1)	Uhlig et al. (2018) (2)	Klatte et al. (2014) (3)	Tang et al. (2014) (4)
Andrews et al. (2019)	●			
Atwell et al. (2013)		●		
Bhindi et al. (2017)		●		
Camacho et al. (2016)		●		
Caputo et al. (2017)	●	●		
Chehab et al. (2016)		●		
Danzig et al. (2015)		●		
Desai et al. (2005)	●	●	●	●
Emara et al. (2014)		●	●	●
Fosatti et al. (2015)	●			
Foyil et al. (2008)		●		
Garcia et al. (2021)	●			
Guillotreau et al. (2012)	●	●	●	●
Haber et al. (2012)		●	●	●
Haramis et al. (2012)	●	●	●	●
Hegarty et al. (2006)		●		
Hinshaw et al. (2016)		●		
Hruby et al. (2006)			●	●
Kim et al. (2007)			●	
Kiriluk et al. (2006)				●
Klatte et al. (2011)	●	●		
Ko et al. (2008)	●			
Lian et al. (2010)			●	
Lin et al. (2008)			●	●
Liu et al. (2021)	●			

Lughezzani et al. (2009)			●	
Mason et al. (2017)		●		
Nisbett et al. (2009)			●	
O'Malley et al. (2007)		●	●	●
Panumatrassamee et al. (2013)		●		
Rembeyo et al. (2019)	●			
Tanagho et al. (2013)		●		
Thompson et al. (2015)		●		
Turna et al. (2009)		●	●	
Weinberg et al. (2015)		●		
Yanagusawa et al. (2018)	●			
Zechlinski et al. (2016)		●		

Table 2a. Systematic Reviews and Meta-Analyses Comparing Cryoablation to Partial Nephrectomy-Study Characteristics

Study	Search End Date	Study Inclusion	Studies Included
Yanagisawa et al. (2022) (1)	August 2021	Compared ablation therapy (AT) (RFA, MWA, or cryoablation) with PN in the treatment of cT1a and cT1b renal tumors. Reported on clinical outcomes, which included complication rate, hospitalization period, % decline in estimated glomerular filtration rate (eGFR), recurrence, secondary efficacy, metastasis, and mortality from disease. Retrospective and prospective studies were included.	Total = 27 (13,996 patients) 12 studies focused on cryoablation compared with PN
Uhlig et al. (2008) (2)	December 2017	Evaluated PN, RFA, cryoablation, or MWA for treatment of renal masses; Comparative study design contrasting at least 2 different interventions; Assessed at least 1 of the following end points: all-cause mortality, cancer-specific mortality, local recurrence, complications or change in renal function. Retrospective and prospective studies were included.	Total = 47 (24,077 patients) 13 prospective, 34 retrospective Cryoablation: 24 studies (668 patients)
Klatte et al. (2014) (3)	September 2013	Compared laparoscopic cryoablation with laparoscopic PN or robot-assisted laparoscopic PN for the treatment of small	Total = 13 (1191 patients) All retrospective

		renal tumors; Reported perioperative outcomes or data on histology and oncologic outcomes were provided.	
Tang et al. (2014) (4)	September 2013	Compared laparoscopic cryoablation and laparoscopic PN for small renal masses; Reported on at least 1 of the following outcomes: operating time, estimated blood loss, length of hospital stay, blood transfusion rate, conversions rate, postoperative serum creatinine increase, postoperative glomerular filtration rate decrease, catheterization time, local recurrence, distant metastasis, and overall complications, including both intraoperative and postoperative minor and major complications; Clearly documented indications for resection of the renal tumor.	Total = 92 prospective, 7 retrospective

MWA: microwave ablation; PN: partial nephrectomy; RFA: radiofrequency ablation

Table 2b. Systematic Reviews and Meta-Analyses Comparing Cryoablation to Partial Nephrectomy-Study Characteristics

Study	Mean Tumor Size	Sample Size	Follow-up Duration (months)
Yanagisawa et al. (2022) (1)	18 studies comprise cT1a patients, 6 studies comprise cT1b patients, and 3 studies include both	cT1a: 13,062 cT1b: 934	Not described
Uhlig et al. (2008) (2)	Cryoablation: 2.53 cm PN: 2.84 cm MWA: 2.74 cm RFA: 2.63 cm	Cryoablation: 6,618 PN: 15,238 MWA: 344 RFA: 1,877	Range 3 to 82
Klatte et al. (2014) (3)	Cryoablation: 2.28 cm PN: 2.41 cm	Cryoablation: 627 PN: 564	Mean Cryoablation: 22.5 PN: 29.5
Tang et al. (2014) (4)	Not reported	Cryoablation: 555 PN: 642	Range Cryoablation: 11.9 to 44.5 PN: 4.8 to 42.7

MWA: microwave ablation; PN: partial nephrectomy; RFA: radiofrequency ablation

Yanagisawa et al. (2022) published a systematic review and meta-analysis comparing ablative therapies (cryoablation, radiofrequency ablation (RFA), and microwave ablation) to partial nephrectomy. (1) Twenty-seven trials published between 2005 and 2021 (N=13,996) were

included; 12 of those studies directly compared cryoablation with partial nephrectomy, although results were not stratified by type of ablative therapy (see Table 3). No significant differences in cancer-specific mortality for cT1a tumors ($p=.50$) and cT1b tumors ($p=.63$) were found comparing partial nephrectomy and ablation therapies. Local recurrence was higher for ablative therapies compared with partial nephrectomy in both cT1a tumors (risk ratio, 0.43; 95% confidence interval [CI], 0.28 to 03.66; $p=.0001$) and cT1b tumors (risk ratio, 0.41; 95% CI, 0.23 to 0.75; $p=.004$). There were no significant differences between partial nephrectomy and ablation therapy in terms of rate of metastases, overall complications, and decline in renal function.

Uhlig et al. (2019) published a systematic review and meta-analysis comparing partial nephrectomy, RFA, cryoablation, and microwave ablation for small renal masses. (2) Forty-seven studies published between 2005 and 2017, with a total of 24077 participants, were included. Of these, 24 studies conducted in 668 patients, compared cryoablation to partial or another ablative technique. Table 3 summarizes the results of the network meta-analysis for the comparison of cryoablation to partial nephrectomy. No significant difference in cancer-specific mortality for PN ($p=0.8065$), CRA ($p=0.5519$), RFA ($p=0.3496$), and MWA ($p=0.2920$) was found. Local recurrence was higher for CRA, RFA, and MWA compared with PN (respectively, incidence rate ratio=4.13; incidence rate ratio=1.79; incidence rate ratio=2.52; $p<0.05$). There was a less pronounced decline in renal function for RFA compared with PN, CRA, and MWA (respectively, mean difference in glomerular filtration rate =6.49; mean difference=5.82; mean difference MD=10.89; $p<0.05$).

Tang et al. (2014) reported on a systematic review and meta-analysis comparing laparoscopic renal cryoablation (LRC) with laparoscopic partial nephrectomy in the treatment of small renal masses. (4) Reviewers identified 9 trials (2 prospective, 7 retrospective) in which the 2 techniques were assessed (555 cases, 642 controls). LRC was associated with statistically significant shorter surgical time, less blood loss, and fewer overall complications; however, it was estimated that laparoscopic partial nephrectomy may still have a significantly lower local recurrence rate (OR=13.03; 95% CI, 4.20 to 40.39; $p<0.001$) and lower distant metastasis rate (OR=9.05; 95% CI, 2.31 to 35.51; $p=0.002$).

Klatte et al. (2014) also reported on a systematic review and meta-analysis comparing LCA with laparoscopic partial nephrectomy for small renal tumors. (3) Thirteen nonrandomized studies were selected for analysis, which found LCA was associated with better perioperative outcomes than laparoscopic partial nephrectomy. Oncologic outcomes, however, were inferior with cryoablation, which was significantly associated with greater risk of local (RR=9.39) and metastatic (RR=4.68) tumor progression.

Table 3. Systematic Reviews and Meta-Analyses Comparing Cryoablation to Partial Nephrectomy Study Results

Study	All-Cause Mortality	Cancer-Specific Mortality	Local Recurrence	Metastases	Complications	Decline in Renal Function

Yanagisawa et al. (2022) (1)						
cT1a tumors: Risk ratio (95% CI); p-value	Not assessed	0.87 (0.57 to 1.31);.50	0.43 (0.28 to 0.66);.0001 Favors PN	0.79 (0.47 to 1.34);.39	1.34 (0.90 to 2.0);.15	MD, 2.42 (-0.06 to 4.89);.06
I ² (P-value)		0% (.62)	20% (.23)	20% (.28)	63% (.0003)	83% (.0004)
cT1b tumors: Risk ratio (95% CI); p-value	Not assessed	0.80 (0.32 to 1.98);.63	0.41 (0.23 to 0.75);.004 Favors PN	1.16 (0.51 to 2.64);.72	1.08 (0.76 to 1.53);.68	MD, 0.73 (-3.76 to 5.23);.75
I ² (P-value)		0% (.76)	30% (.20)	28% (.23)	22% (.26)	0% (.71)
Uhlig et al. (2019) (2)						
Network meta-analysis Cryoablation vs PN IRR (95% CI) P	2.58 (1.92 to 3.46) <.001	2.27 (0.79 to 6.49) .126	4.13 (2.28 to 7.47) .001	Not assessed	0.67 (0.48 to 0.92) .013	0.66 (-3.18 to 4.51) .736
I ² (P-value)	0% (.968)	0% (.8283)	29.4% (.6784)		59.9% (.003)	91.8% (.9001)
Klatte et al. (2014) (3)						
Relative Risk (95% CI); P-value	Not assessed	Not assessed	Local Progression: 9.39 (3.83 to 22.98); <.0001	Metastatic Progression: 4.68 (1.88 to 11.64); <.001	Complications Total: 1.82 (1.22 to 2.72) Urological: 1.99 (1.10 to 3.63) Non-urological: 2.33 (1.42 to 3.84) Favors cryoablation	Not assessed
Tang et al. (2014) (4)						
Odds Ratio/Weighted Mean Difference (95% CI); P-value	Not assessed	Not assessed	13.03 (4.20 to 40.39); <.001	9.05 (2.31 to 35.51);.002	Overall: 0.53 (0.29 to 0.98);.04 Major: 0.45 (0.25 to 0.81);.008 Minor: 0.65	SCr % increase: -6.77 (-13.79 to 0.24);.06 GFR decrease

					(0.33 to 1.28);.21 Postoperative: 0.61 (0.32 to 1.15);.13 Intraoperative : 0.20 (0.07 to 0.58);.003	: -1.83 (-7.61, 3.96);.44
I ² (P-value)			5% (.38)	0% (.79)	Overall: 61% (.009) Major: 0% (.48) Minor: 53% (.03) Postoperative: 60% (.01) Intraoperative : 0% (.89)	SCr % increase: 61% (.08) GFR decrease : 79% (.002)

CI: confidence interval; GFR: glomerular filtration rate; IRR: incidence rate ratio; PN: partial nephrectomy; SCr: serum creatinine; MD: mean difference.

Comparative Observational Studies

This section summarizes recent comparative studies of cryoablation and partial nephrectomy not included in any of the systematic reviews discussed above.

Andrews et al. (2019) reported on 1798 patients with primary stage 1 renal masses treated with partial nephrectomy, percutaneous RFA, or percutaneous cryoablation between 2000 and 2011 at Mayo Clinic. (5) A total of 1422 patients were treated with partial nephrectomy (n=1055), RFA (n=180), or cryoablation (n=187) for stage 1a renal masses, and 376 patients were treated with partial nephrectomy (n=324) or cryoablation (n=52) for stage 1b renal masses. Comparisons of cryoablation to partial nephrectomy among 1422 patients with stage 1a masses resulted in hazard ratios (HRs) of 1.88 (95% CI 0.76 to 4.66, p=.18), 0.23 (95% CI, 0.03 to 1.72, p=.15), and 0.29 (95% CI, 0.01 to 6.11, p=.40) for local recurrence, metastases, and death from renal cell carcinoma. Five-year cancer-specific survival was 99%, 96%, and 100% for partial nephrectomy, RFA, and cryoablation, respectively. Among 376 stage 1b patients, 324 and 52 underwent partial nephrectomy and cryoablation with median clinical follow-up of 8.7 and 6.0 years, respectively. Comparisons of cryoablation with partial nephrectomy resulted in HRs of 1.22 (95% CI, 0.33 to 4.48, p=.80), 0.95 (95% CI, 0.21 to 4.38, p>.90), and 1.94 (95% CI, 0.42 to 8.96, p=.40) for local recurrence, metastases, and death from renal cell carcinoma, respectively. Five-year cancer specific survival was 98% and 91% for partial nephrectomy and cryoablation, respectively.

A retrospective, nonrandomized analysis of prospectively collected data compared robot-assisted partial nephrectomy with percutaneous ablation in patients with T1b renal cell

carcinoma. Rembeyo et al. (2020) compared patients treated with robot-assisted PN (n=36), CRA (n=55), and RFA (n=11). (6) Median tumor sizes in each group were 4.5, 4.6, and 4.2 cm, respectively, and median follow-up times were 23.7, 19.9, and 51.3 months. Compared with PN, local recurrence-free survival was significantly shorter with CRA (adjusted HR, 4.3; 95% CI, 1.78-10.37). Two-year local recurrence-free survival rates for the PN, CRA, and RFA groups were 89.1%, 73.5%, and 81.8%, respectively (p<0001).

A retrospective, nonrandomized study also compared PN with CRA and RFA, specifically in patients with T1aN0M0 renal cell carcinoma with tumor size ≤4 cm. Yan et al. (2019), using Medicare Surveillance, Epidemiology, and End Results (SEER) data, compared OS and cancer-specific survival in patients treated with PN (n=15,395), CRA (n=1,381), and RFA (n=457). (7) Median follow-up was 30 months in all groups. OS was significantly improved with PN compared with CRA (HR, 2.995; 95% CI, 2.363 to 3.794) and RFA (HR, 4.085; 95% CI, 2.683 to 6.220). Similarly, cancer-specific survival was significantly improved with PN compared with CRA (HR, 3.562, 95% CI, 1.399–6.220) and RFA (HR, 3.457; 95% CI, 2.043 to 5.850). In subgroup analyses of patients with tumor size ≤2 cm, OS was again significantly improved with PN versus CRA (HR 1.958; 95% CI, 1.204 to 3.184) and RFA (HR, 2.841; 95% CI, 1.211 to 6.662); however, cancer-specific survival was not different. In patients with tumor size 2 to 4 cm, OS was significantly improved with PN versus CRA (HR 3.284; 95% CI, 2.513 to 4.292) and versus RFA (HR, 4.497; 95% CI, 2.782 to 7.269), as was cancer-specific survival (PN vs. CRA: HR, 3.536; 95% CI, 2.006 to 6.234; PN vs RFA: HR, 4.339; 95% CI, 1.573 to 11.971).

Another analysis of Medicare SEER data retrospectively compared PN with CRA in patients with T1b nonmetastatic renal cell carcinoma. Pecoraro et al. (2019) compared patients undergoing CRA (n=434) with propensity score-matched patients undergoing PN (n=228). (8) In patients treated with CRA versus PN at 5 years, cancer-specific mortality rates were 7.6% versus 2.8%, respectively (p=0.02), and other-cause mortality rates were 17.9% versus 11.8% (p=0.1). Findings were consistent in multivariable analyses, where other-cause mortality remained nonsignificant, and CRA was associated with higher risk of mortality (adjusted HR, 2.50).

Section Summary: Patients Who Are Surgical Candidates

Multiple comparative observational studies and systematic reviews of these studies have compared cryoablation to partial nephrectomy for early-stage renal cancer. These studies have consistently found that partial nephrectomy is associated with better oncological outcomes than cryosurgery.

Patients Who Are Not Surgical Candidates

There are no RCTs or comparative observational studies comparing cryoablation to active surveillance in patients with kidney cancer that were identified.

Systematic Reviews

Although there are no systematic reviews directly comparing cryoablation with active surveillance in patients who are not surgical candidates, multiple systematic reviews of cryoablation compared to surgery or other ablative strategies have reported on outcomes in

patients who received cryoablation for kidney tumors. These reviews consistently found that although oncological outcomes were better with surgery, cryoablation was associated with better perioperative outcomes, lower incidence of complications, and less decline in kidney function (see Table 2a, 2b and 3).

Case Series

In a review of strategies for treating stage 1 renal cell carcinoma, Cronan et al. (2019) identified 17 articles published since 2010 describing 2,320 lesions treated with cryoablation. (9) Mean tumor size was 2.6 cm. The overall recurrence rate was 8.1% in studies with overall median follow-up of 41.4 months, and the technical success rate was 94.3%. Five-year OS and cancer-specific survival rates were 77.1% to 97.8% and 88% to 100%, respectively. Of the 568 lesions treated since 2016, the local recurrence rate was 3.0%. Renal function was not assessed in this review.

Recent case series have shown cryoablation associated with good oncological outcomes and preservation of renal function (Table 4).

In a single-center series reported by Morkos et al. (2020), 5 of 132 patients (3.8%) transitioned to hemodialysis. (10) The dialysis-free probability was 98% (95% CI, 0.95 to 1) at 5 years, and 95% (95% CI, 0.89 to 1) at 10 years.

In a series of 338 patients treated at 4 centers in Italy, Stacul et al. (2021) reported that 93.3% of patients treated with cryoablation did not experience a significant decrease in renal function. (11)

Table 4. Renal Function Outcomes in Longer-Term Observational Studies and Case Series of Cryoablation for Kidney Tumors

Study	Setting	N	Mean Tumor Size	Follow-up Duration	Oncological Outcomes	Renal Function Outcomes
Morkos et al. (2020) (10)	Single center	134	2.8 cm (SD±1.4 cm); range, 0.5 to 7.0 cm	10 years	Survival: 87% (95% CI, 80% to 93%) at 5 years; 72% (95% CI, 62% to 83%) at 10 years RFS: 85% (95% CI, 79% to 91%) at 5 years; 69%	5 of 132 (3.8%) transitioned to hemodialysis Dialysis-free probability (95% CI): At 5 years: 98% (95% to 100%) At 10 years: 95% (89% to 100%)

					(95% CI, 59% to 79%) at 10 years Disease-specific survival: 94% (95% CI, 90% to 98%) at both 5 years and 10 years.	
Stacul et al. (2021) (11)	4 centers in North-Eastern Italy	338	2.53 cm	5 years	RFS: 90.5% (95% CI, 83.0% to 94.9%) at 3 years and 82.4% (95% CI, 72.0% to 89.4%) at 5 years OS: 96.0% (95% CI, 90.6% to 98.3%) at 3 years and 91.0% (95% CI, 81.7% to 95.7%) at 5 years	Cryoablation was not associated with a significant decrease in renal function after treatment in 93.3%

CI: confidence interval; OS: overall survival; RFS: recurrence-free survival

Section Summary: Patients who Are Not Surgical Candidates

The evidence on cryoablation in patients with kidney cancer who are not surgical candidates consists of comparative observational studies of cryoablation compared to partial nephrectomy or other ablative techniques, systematic reviews of these studies, and case series. Although oncological outcomes were better with surgery, cryoablation was associated with less decline in kidney function. Recent case series totaling more than 400 patients showed cryoablation was associated with good oncological outcomes and preservation of renal function.

Non-Small Cell Lung Cancer
Clinical Context and Therapy Purpose

The purpose of cryoablation is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with non-small cell lung cancer (NSCLC).

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with NSCLC.

The review of evidence addresses the use of cryoablation in 2 populations of patients who have NSCLC:

1. Patients with NSCLC who are not surgical candidates;
2. Patients with NSCLC who require palliation for a central airway obstructing lesion.

Interventions

The therapy being considered is cryoablation, also referred to as cryosurgery.

Cryoablation involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Comparators

For medically operable NSCLC, surgery is preferred. For patients who are medically inoperable, who refuse surgery, or who are high-risk surgical candidates, radiation therapy has a potential role, as either definitive or palliative therapy.

For patients who require palliation for a central airway obstructing lesion, standard symptom palliative care is radiation. Chemotherapy, stent placement, and other ablative bronchoscopic therapies are also options.

Outcomes

The general outcomes of interest are OS, disease-specific survival, quality of life, and treatment-related morbidity.

The hypothesized advantages of cryosurgery for NSCLC include improved local control and benefits common to any minimally invasive procedure (e.g., preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization).

Potential complications of cryosurgery include those caused by hypothermic damage to normal tissue adjacent to the tumor, structural damage along the probe track, and secondary tumors if cancerous cells are seeded during probe removal.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- Comparative controlled prospective trials were sought, with a preference for RCTs.

- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that captured longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Patients with Non-Small Cell Lung Cancer who are not Surgical Candidates

Systematic Reviews

Lee et al. (2011) conducted a systematic review of endoscopic cryoablation of lung and bronchial tumors. (12) Included in the review were 15 case studies and a comparative observational study. Cryoablation was performed for inoperable, advanced lung and bronchial cancers in most studies. Some studies included patients with comorbid conditions and poor general health who would not be considered surgical candidates. Complications occurred in 11.1% of patients (10 studies) and consisted of hemorrhage, mediastinal emphysema, atrial fibrillation, and dyspnea. Within 30 days of the procedure, death from hemoptysis and respiratory failure, considered to be most likely related to disease progression, occurred in 7.1% of patients.

Niu et al. (2012) reviewed the literature on lung cryoablation and reported on their own experience with PCA in 150 patients with non-small-cell lung cancer (NSCLC) followed for 12 to 38 months. (13) The study population had stage IIIB or IV lung cancer. OS rates at 1, 2, and 3 years were 64%, 45%, and 32%, respectively. Thirty-day mortality was 2.6% and included cardiac arrest and hemopneumothorax. Complications included hemoptysis, pneumothorax, hemothorax, pleural effusion, and pulmonary infection.

Nonrandomized Studies

The Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE) assessed the safety and local recurrence-free survival after cryoablation for treatment of pulmonary metastases. Callstrom et al. (2020) performed this multicenter, prospective, single-arm, phase 2 study in 128 patients with 224 lung metastases ≤ 3.5 cm. (14) Median tumor size was 1.0 cm. Local recurrence-free response was 85.1% at 12 months and 77.2% at 24 months. Secondary local recurrence-free response after retreatment with cryoablation for recurrent tumors was 91.1% at 12 months and 84.4% at 24 months. OS at 12 and 24 months was 97.6% and 86.6%, respectively.

The Evaluating Cryoablation of Metastatic Lung/pleura Tumors in Patients-Safety and Efficacy trial (ECLIPSE) is a prospective, multicenter trial of cryoablation for metastatic disease in the lungs, interim results at 1-year follow-up were published by de Baere et al. (2015). (15) The trial enrolled 40 patients with 60 metastatic lung lesions who were treated with cryoablation and had at least 12 months of follow-up. Outcomes included survival, local tumor control, quality of life, and complications. Local tumor control was achieved in 94.2% (49/52) of treated lesions, and 1-year OS was 97.5% (39/40). There were no significant changes in quality of life over the 12-month study. The most common adverse event was pneumothorax requiring chest tube insertion in 18.8% (9/48 procedures). No subsequent analyses were identified.

Moore et al. (2015) reported on a retrospective case review of 45 patients (47 tumors) managed with cryoablation during a 5-year period (2006-2011). (16) All patients had biopsy-proven early-stage (T1a and T1b) primary lung tumors and had been assessed by a tumor board to be medically inoperable. Lesions were as small as 5 mm, with an average of 1.9 cm (range, 0.5-3 cm). Cryoablation procedures were performed under general anesthesia. The primary end point was the completion of the freeze-thaw cycle. Mean follow-up was 51 months, with an observed 5-year survival rate of 67.8%, 5-year cancer-specific survival rate of 56.6%, and 5-year progression-free survival rate of 87.9%. There were 7 (14.8%) local recurrences; two had device failure and retreatment, and another had retreatment for a recurrence at 1 year after initial treatment. The ablation zone was less than 5 mm outside the margin of the tumor in 5 of the 47 treatments, and 4 of these 5 had local recurrences. Complications primarily included 19 (40%) patients with hemoptysis, two of which required bronchoscopy, and 24 (51%) cases of pneumothorax, 1 of which required surgical chest tube with prolonged placement and mechanical sclerosis. Three (6.4%) patients were considered to have major complications (requiring bronchoscopy or chest tube described in the previous statement), but there were no reports of 30-day mortality.

Section Summary: Patients With Non-Small Cell Lung Cancer who are not Surgical Candidates

Medically inoperable patients with early-stage primary lung tumors were treated with cryoablation in a consecutive series of 45 patients. Five-year survival was 68%; the main complications were hemoptysis in 40% of patients and pneumothorax in 51%. A prospective single arm Phase 2 study of 128 patients reported on cryoablation for treatment of metastases to the lung. Cryoablation for metastatic lung cancer was studied in a single arm trial in 40 patients.

Patient with Non-Small Cell Lung Cancer who Require Palliation for a Central Airway Obstruction

Systematic Review

Ratko et al. (2013) conducted a comparative effectiveness review on local nonsurgical therapies for stage I and symptomatic obstructive non-small-cell lung cancer for the Agency for Healthcare Research and Quality. (17) CRA was included as a potential therapy for airway obstruction due to endoluminal non-small-cell lung cancer. The reviewers identified 1 RCT that randomly allocated patients to external beam radiation therapy or endobronchial treatment (clinician choice of any one endobronchial treatment: brachytherapy, laser therapy or cryotherapy). The trial was discontinued before completion due to lack of patient accrual, and therefore the reviewers did not include the trial in their report. Reviewers were unable to draw any conclusions about local nonsurgical therapies, including CRA, due to lack of quality evidence.

Consecutive Case Series

Maiwand and Asimakopoulos (2004) reported on a large case series of 521 patients with symptomatic obstructive tracheobronchial malignant tumors who underwent cryosurgery with a mean of 2.4 treatments per patient. (18) The patients were treated between 1995 and 2003,

had a mean age of 67.9 years, and 72% were diagnosed with stage IIIb or IV disease. Improvement in one or more symptoms (hemoptysis, cough, dyspnea, chest pain) was demonstrated in 86.0% of patients. Postoperative complications were 9%, including 21 (4%) cases of hemoptysis, 12 (2%) cases of postoperative atrial fibrillation, and 16 (3%) patients developed respiratory distress and poor gas exchange that eventually resolved. There were 7 (1.2%) in-hospital deaths (cause of death was respiratory failure in all 7 patients).

This study has several limitations, which are summarized in Tables 5 and 6.

Table 5. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-up ^e
Maiwand and Asimakopoulos (2004) (18)	3. Patients were treated 20 to 30 years ago	1. Patients were treated 20 to 30 years ago; replicable across other institutions.	2. No comparator; radiation is standard of care and other treatment options are available.	5. No description of what size improvement is important	1,2. The duration of follow-up was not described for the 521 patients (it was described for the 15 with cryosurgery at exploratory thoracotomy but those are not relevant here). The timing of the outcome measures is unclear. It is unclear if patients were evaluated on a standard schedule and at what time point improvements were seen.

The study limitations stated in this table are those notable in the current literature review; this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as

comparator; 4. Not the intervention of interest.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 6. Study Design and Conduct Limitations

Study	Allocation^a	Blinding^b	Selective Reporting^c	Data Completeness^d	Power^e	Statistical^f
Maiwand and Asimakopoulos (2004) (18)	4. No comparator, not randomized . Not clear why these patients were chosen for cryosurgery versus one of the other procedures that are available for these patients (selection bias) at this institution.	3. No blinding. All of these measures are subjective. Although these symptoms would likely not improve without treatment, the symptom reports and physician assessment of performance status are potentially biased which is complicated by the fact that there is no comparator.		1. No description of patient flow or the amount of available data for any of the outcome measures.		

The study limitations stated in this table are those notable in the current literature review; this is not a comprehensive gaps assessment.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Section Summary: Patients with Non Small Cell Lung Cancer who Require Palliation for a Central Airway Obstructing Lesion

There are no comparative studies. A case series of 521 consecutive patients reported improvement in symptoms in 86% of patients, but multiple study design, conduct, and relevance limitations preclude drawing conclusions about efficacy or safety of cryoablation in this population.

Solid Tumors Located in the Breast, Pancreas, or Bone

Clinical Context and Therapy Purpose

The purpose of cryoablation is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with solid tumors in the breast, pancreas, or bone.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with tumors in the breast, pancreas, or bone.

Interventions

The therapy being considered is cryoablation, also referred to as cryosurgery.

Cryoablation involves freezing of target tissues; this is most often performed by inserting a coolant-carrying probe into the tumor. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

Comparators

Comparators of interest include surgical resection, other ablative techniques such as laser surgery, RFA, irreversible electroporation, and argon beam coagulation.

Regarding tumors located in the breast, the selection of lumpectomy, modified radical mastectomy, or another approach is balanced against the patient's desire for breast conservation, the need for tumor-free margins in resected tissue, and the patient's age, hormone receptor status, and other factors.

Palliative treatments for bone metastases include analgesics, opioids, osteoclast inhibitors, and radiation therapy.

Outcomes

The general outcomes of interest are OS, disease-specific survival, quality of life, and treatment-related morbidity.

The hypothesized advantages of cryosurgery include improved local control and benefits common to any minimally invasive procedure (e.g., preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization).

Potential complications of cryosurgery include those caused by hypothermic damage to normal tissue adjacent to the tumor, structural damage along the probe track, and secondary tumors if cancerous cells are seeded during probe removal.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- Comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that captured longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Breast Tumors

Systematic Reviews

Zhao and Wu (2010) reported on a systematic review of minimally invasive ablative techniques of early-stage breast cancer. (19) They noted that studies assessing cryoablation for breast cancer were primarily pilot and feasibility studies. Complete ablation of tumors was found to be reported within a wide range (36%-83%). Reviewers raised many areas of uncertainty, including patient selection criteria and the ability to precisely determine the size of tumors and achieve 100% tumor cell death. They suggested minimally invasive thermal ablation techniques for breast cancer treatment, including CRA, be limited until results from prospective, RCTs become available.

Randomized Controlled Trials

A prospective, single-arm, phase 2 trial was published by Simmons et al. for the American College of Surgeons Oncology Group Z1072 in 2016. (20) This trial enrolled 86 evaluable patients from 19 institutions with invasive ductal breast carcinoma that was 2 cm or less in size. The primary end point was complete ablation, defined as no residual evidence of tumor on magnetic resonance imaging. The investigators assigned a priori the success rates indicating that cryoablation would be a potentially efficacious treatment (>90%) or that the results of cryoablation would be unsatisfactory (<70%). Following cryoablation and determination of complete ablation, all patients underwent surgery according to standard protocols for treatment of early breast cancer. Of 87 cancers in 86 patients, complete ablation was achieved in 66 (75.9%; 95% confidence interval [CI], 67.1% to 83.2%). Most cases without complete ablation were the result of multifocal disease outside the targeted lesion.

Nonrandomized Studies

Niu et al. (2013) reported on a retrospective study of 120 patients with metastatic breast cancer, including 30 metastases to the contralateral breast and other metastases to the lung, bone, liver, and skin who were treated with chemotherapy (n=29) or cryoablation (n=91, 35 of whom also received immunotherapy). (21) At 10-year follow-up, the median OS of all study participants was 55 months in the cryoablation group versus 27 months in the chemotherapy group ($p<0.001$). Moreover, the median OS was greater in patients receiving multiple cryoablations and in those receiving immunotherapy. Complications with cryotherapy to the breast included ecchymosis and hematoma, pain, tenderness, and edema; all these complications resolved within 1 week to 1 month.

In a case series by Manteni et al. (2011), who assessed 15 breast cancer patients, percutaneous cryoablation (PCA) was performed 30 to 45 days before surgical resection. (22) Resection of the lesions confirmed that complete necrosis had occurred in 14 patients, but 1 lesion had residual disease considered to be due to incorrect probe placement. In a small series of 11 patients with breast cancer tumors less than 2 cm in diameter, Pusztaszeri et al. (2007) found residual tumors present in 6 cases when follow-up lumpectomies were performed approximately 4 weeks after CRA. (23) A case series by Sabel et al. (2004) explored the role of CRA as an alternative to surgical excision as a primary treatment for early-stage breast cancer. (24) This phase 1 study included 29 patients who underwent CRA of primary breast cancers measuring less than 2 cm in diameter, followed 1 to 4 weeks later by standard surgical excision. CRA was successful in patients with invasive ductal carcinoma less than 1.5 cm in diameter, and with less than 25% ductal carcinoma in situ identified in a prior biopsy specimen.

Other studies have described outcomes from cryosurgery for advanced primary or recurrent breast cancer. (25-28) Collectively, these reports either did not adequately describe selection criteria for trial enrollees, procedure details, or procedure-related adverse events or had inadequate study designs, analyses, and reporting of results.

Breast Fibroadenomas

A variety of case series have focused on the role of cryosurgery as an alternative to surgical excision of benign fibroadenomas. Kaufman et al. (2002-2005) have published several case series on office-based ultrasound-guided CRA as a treatment of breast fibroadenomas. (29-33) These case series reported on a range of 29 to 68 patients followed for 6 months to 2.6 years. It is likely that these case series included overlapping patients. At 1 year, patients reported 91% patient satisfaction and fibroadenomas became nonpalpable in 75% of cases. At follow-up averaging 2.6 years in 37 patients, the authors noted only 16% of 84% palpable fibroadenomas remained palpable after treatment and, of the fibroadenomas initially 2 cm or less in diameter, only 6% remained palpable. (33) In this series, the authors also noted that cryoablation did not produce artifacts that could interfere with interpretation of mammograms. These small case series, which were done by the same group of investigators, are inadequate to permit scientific conclusions.

Nurko et al. (2005) reported on outcomes at 6 and 12 months for 444 treated fibroadenomas reported to the FibroAdenoma Cryoablation Treatment registry by 55 different practice settings. (34) In these patients, before cryoablation, 75% of fibroadenomas were palpable by the patient. Follow-up at 6- and 12-month intervals showed palpable masses in 46% and 35%, respectively. When fibroadenomas were grouped by size, the treatment area was palpable in 28% of subject for lesions 2 cm or less in diameter and 59% for more than 2 cm at 12 months.

Subsection Summary: Breast Tumors

For the treatment of primary and recurrent breast cancer, available evidence has shown that complete ablation can be achieved in most cases for variably defined small tumors, but studies do not include control groups or compare outcomes of cryosurgery with alternative strategies for managing similar patients. Therefore, no conclusions can be made on the net health outcomes of cryosurgery for breast cancer. For treatment of fibroadenomas, there is a small amount of evidence. This evidence has demonstrated that most fibroadenomas become “nonpalpable” following cryoablation. However, there is a lack of comparative trials. Comparative trials with adequate long-term follow-up are needed to assess this technology and determine how this approach compares with surgery, as well as with vacuum-assisted excision and with observation (approximately one-third of fibroadenomas regress over time after cryoablation).

Pancreatic Cancer

Systematic Reviews

Tao et al. (2012) reported on a systematic review of cryoablation for pancreatic cancer. (35) Reviewers identified 29 studies and selected 5. All 5 were case series and considered of low quality. Adverse events, when mentioned, included delayed gastric emptying (0%-40.9% in 3 studies), pancreatic leak (0%-6.8% in 4 studies), biliary leak (0%-6.8% in 3 studies), and a single instance of upper gastrointestinal hemorrhage. Pain relief was reported in 3 studies and ranged from 66.7% to 100%. Median survival times reported in 3 studies ranged from 13.4 to 16 months. One-year total survival rates, as reported in 2 studies, were 57.5% and 63.6%. Keane et al. (2014) reported on a systematic review of ablation therapy for locally advanced pancreatic cancer. (36) Reviewers noted that studies had demonstrated ablative therapies, including cryoablation, are feasible, but larger studies are needed. No conclusions could be made on whether ablation resulted in better outcomes than best supportive care.

Nonrandomized Trials

Li et al. (2011) reported on a retrospective study of 142 patients with unresectable pancreatic cancer treated with palliative bypass with (n=68) or without cryoablation (n=74) from 1995 to 2002. (37) Median dominant tumor sizes decreased from 4.3 to 2.4 cm in 36 (65%) of 55 patients 3 months after cryoablation. Survival rates did not differ significantly between groups, with the cryoablation group surviving a median of 350 days versus 257 days in the group without cryoablation. Complications did not differ significantly between groups. However, a higher percentage of delayed gastric emptying occurred in the cryoablation group (36.8%) than in the group without cryoablation (16.2%).

A pilot study on combination cryosurgery plus iodine 125 seed implantation for treatment of locally advanced pancreatic cancer was reported by Xu et al. (2008). (38) Forty-nine patients enrolled in the pilot study, and 12 had liver metastases; 20 patients received regional chemotherapy. At 3 months posttherapy, most patients showed tumor necrosis, with 20.4% having a complete response. Overall, the 6-, 12-, 24-, and 36-month survival rates were 94.9%, 63.1%, 22.8%, and 9.5%, respectively.

Kovach et al. (2002) reported on 10 cryosurgical ablations in 9 patients with unresectable pancreatic cancer using intraoperative ultrasound guidance during laparotomy. (39) The authors reported adequate pain control in all patients postoperatively and no intraoperative morbidity or mortality. At publication, all patients had died at an average of 5 months postoperatively (range, 1-11 months).

Subsection Summary: Pancreatic Cancer

The available evidence on cryosurgery for pancreatic cancer consists of retrospective case series that used cryosurgery for palliation of inoperable disease and a systematic review of these studies. These studies reported that pain relief is achieved in most cases and that complications (e.g., delayed gastric emptying) are common, but the true rate of complications is uncertain. Because these studies did not include control groups or compare outcomes of cryosurgery with alternative strategies for managing similar patients, no conclusions can be made on the net health outcomes of cryosurgery for pancreatic cancer.

Bone Cancer and Bone Metastases

Meller et al. (2008) retrospectively analyzed a single-center experience of 440 bone tumor cryosurgery procedures performed between 1988 and 2002, two-thirds of them for primary benign-aggressive and low-grade malignant lesions, and one-third for primary high-grade and metastatic bone tumors. (40) At a median follow-up of 7 years (range, 3-18 years), the overall recurrence rate was 8%. Based on their experience, the authors suggested that the ideal case for cryosurgery is a young adult with involvement of long bone, a benign-aggressive or low-grade malignant bone tumor, a good cavity with greater than 75%-thick surrounding walls, none or minimal soft-tissue component, and at least ± 1 cm of subchondral bone left near a joint surface after curettage and burr drilling.

Callstrom et al. (2013) reported on 61 patients treated with cryoablation for pain from 69 tumors (size, 1-11 cm) metastatic to the bone. (41) Before treatment, patients rated their pain with a 4+ on a 1-to-10 scale using the Brief Pain Inventory, with a mean score of 7.1 for worst pain in a 24-hour period. The mean pain score gradually decreased after cryoablation to 1.4 ($p < 0.001$) at 24 weeks for worst pain in a 24-hour period. A major complication of osteomyelitis was experienced by 1 (2%) patient.

Jennings et al. (2021) reported on a multicenter, single-arm prospective study of 66 patients with metastatic bone disease who were treated with cryoablation, all of whom were not candidates for or had not benefited from standard therapy. (42) The primary endpoint was the change in pain score from baseline to week 8 and patients were followed for 24 weeks. The

mean decrease in pain score from baseline to week 8 was 2.61 points (95% CI 3.45 to 1.78). Pain scores decreased further after the primary endpoint and reached clinically meaningful levels (more than a 2-point decrease) after week 8. This study was limited by its lack of a comparator, potential for selection bias, and lack of blinding combined with subjective outcome measures.

Subsection Summary: Bone Cancers and Bone Metastases

There is a small amount of literature on cryoablation for bone cancers and bone metastases. For bone metastases, the evidence base consists of 2 single arm nonrandomized studies (N =61 and 66) and is inadequate to determine efficacy. Studies were limited by a lack of a comparator, potential for selection bias, and lack of blinding combined with subjective outcome measures.

Summary of Evidence

For individuals with early-stage kidney cancer who are surgical candidates treated with cryoablation, the evidence includes comparative observational studies and systematic reviews. Relevant outcomes are overall survival disease-specific survival, quality of life, and treatment-related morbidity. Multiple comparative observational studies and systematic reviews of these studies have compared cryoablation to partial nephrectomy for early-stage renal cancer. These studies have consistently found that partial nephrectomy is associated with better oncological outcomes than cryosurgery, but cryosurgery was associated with better perioperative outcomes, lower incidence of complications, and less decline in kidney function. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with early-stage kidney cancer who are not surgical candidates and who are treated with cryoablation, the evidence includes comparative observational studies of cryoablation compared to partial nephrectomy or other ablative techniques, systematic reviews of these studies, and case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. Although oncological outcomes were better with surgery, in comparative observational studies, cryoablation was associated with less decline in kidney function. Recent case series totaling more than 400 patients showed cryoablation was associated with good oncological outcomes and preservation of renal function. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with non-small cell lung cancer (NSCLC) who are not surgical candidates, the evidence includes uncontrolled observational studies and case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. Medically inoperable patients with early-stage primary lung tumors were treated with cryoablation in a consecutive series of 45 patients. Five-year survival was 68%; the main complications were hemoptysis in 40% of patients and pneumothorax in 51%. A prospective single arm Phase 2 study of 128 patients reported on cryoablation for treatment of metastases to the lung. Cryoablation for metastatic lung cancer was studied in a single arm trial in 40 patients. The

evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with NSCLC who require palliation for a central airway obstructing lesion who are treated with cryoablation, the evidence includes case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. There are no comparative studies. A series of 521 consecutive patients reported improvement in symptoms in 86% of patients, but multiple study design, conduct, and relevance limitations preclude drawing conclusions about efficacy or safety of cryoablation in this population. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with solid tumors located in the breast, pancreas, or bone who are treated with cryoablation, the evidence includes uncontrolled observational studies and case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. Due to the lack of prospective controlled trials, it is not possible to conclude that cryoablation improves outcomes for any indication better than alternative treatments. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with breast fibroadenomas who are surgical candidates treated with cryosurgical ablation, the evidence includes systematic reviews, randomized controlled studies, retrospective studies and case series. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. The available evidence has shown that complete ablation can be achieved in most cases for variably defined small tumors and most fibroadenomas become “nonpalpable” following cryoablation. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with bone cancer who are not surgical candidates the evidence included several prospective studies. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. Minimally invasive palliative cryoablation for inoperable metastatic disease has shown to significantly reduce pain and the painful symptoms associated with the disease. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

American College of Radiology (ACR)

The ACR Appropriateness Criteria (2009, updated 2021) for post-treatment follow up and active surveillance of renal cell carcinoma [RCC] indicated that “Ablative therapies, such as radiofrequency ablation, microwave ablation, and cryoablation have been shown to be an effective and safe alternative [to surgical resection] for the treatment of small, localized RCCs.” (43, 44) These recommendations are based on a review of the data and expert consensus.

American Urological Association

The American Urological Association (2021) updated its guidelines on the evaluation and management of clinically localized sporadic renal masses suspicious for renal cell carcinoma (RCC). (45) The guideline statements on thermal ablation (radiofrequency ablation, cryoablation) are listed in Table 7.

Table 7. Guideline Statements on Localized Masses Suspicious for Renal Cell Carcinoma

Recommendations	LOR	LOE
<i>Guideline statement 25</i>		
Clinicians should consider thermal ablation (TA) as an alternate approach for the management of cT1a renal masses <3 cm in size. For patients who elect TA, a percutaneous technique is preferred over a surgical approach whenever feasible to minimize morbidity.	Moderate	C
<i>Guideline statement 26</i>		
Both radiofrequency ablation and cryoablation are options for patients who elect thermal ablation.	Conditional	C
<i>Guideline statement 28</i>		
Counseling about thermal ablation should include information regarding an increased likelihood of tumor persistence or local recurrence after primary thermal ablation relative to surgical extirpation, which may be addressed with repeat ablation if further intervention is elected	Strong	B

LOE: level of evidence; LOR: level of recommendation.

National Comprehensive Cancer Network (NCCN)

Kidney Cancer

The NCCN (v.4.2023) guidelines on kidney cancer state that "thermal ablation (cryosurgery, radiofrequency ablation) is an option for the management of patients with clinical stage T1 renal lesions. Thermal ablation is an option for masses <3 cm but may also be an option for larger masses in select patients. Ablation in masses >3 cm is associated with higher rates of local recurrence/persistence and complications. Biopsy of small lesions confirms a diagnosis of malignancy for surveillance, cryosurgery, and radiofrequency ablation strategies. Ablative techniques may require multiple treatments to achieve the same local oncologic outcomes as conventional surgery."

The NCCN guidelines also note that "ablative techniques such as cryo- or radiofrequency ablation are alternative strategies for selected patients, particularly the elderly and those with competing health risks." Additionally, the guidelines note that "randomized phase III comparison of ablative techniques with surgical resection (i.e., radical or partial nephrectomy by open or laparoscopic techniques) has not been performed." (46)

Non-Small Cell Lung Cancer

The NCCN (v.5.2023) guidelines for NSCLC made the following relevant recommendations: (47)

- Resection is the preferred local treatment modality for medically operable disease.

- Image-guided thermal ablation (IGTA) techniques include radiofrequency ablation, microwave ablation, and cryoablation.
- IGTA may be an option for select patients not receiving stereotactic ablative radiotherapy or definitive radiotherapy.
- IGTA may be considered for those patients who are deemed "high risk"- those with tumors that are for the most part surgically resectable but rendered medically inoperable due to comorbidities. In cases where IGTA is considered for high-risk or borderline operable patients, a multidisciplinary evaluation is recommended.
- IGTA is an option for the management of NSCLC lesions <3 cm. Ablation for NSCLC lesions >3 cm may be associated with higher rates of local recurrence and complications.
- The guidelines do not separate out recommendations by ablation technique and note that "each energy modality has advantages and disadvantages. Determination of energy modality to be used for ablation should take into consideration the size and location of the target tumor, risk of complication, as well as local expertise and/or operator familiarity."

Cancer Pain

The NCCN Guidelines on Adult Cancer Pain (v.2.2023) do not address cryoablation specifically for pain due to bone metastases but note that "ablation techniques may...be helpful for pain management in patients who receive inadequate relief from pharmacological therapy." (48)

Ongoing and Unpublished Clinical Trials

Some currently unpublished and ongoing trials that might influence this policy are listed in Table 8.

Table 8. Summary of Key Trials

NCT Number	Trial Name	Planned Enrollment	Completion Date
Ongoing			
<i>Renal cancer</i>			
NCT02399124 ^a	ICESECRET PROSENSE™ Cryotherapy for Renal Cell Carcinoma Trial	120	Feb 2026
NCT04506671	A Prospective, Non-randomized, in Parallel Groups Study Evaluating the Efficacy and Safety of Percutaneous Cryoablation and Partial Nephrectomy in Localized T1b Renal Tumor	142	Jun 2025
<i>Breast cancer</i>			
NCT05505643	COOL-IT: Cryoablation vs Lumpectomy in T1 Breast Cancers: A Randomized Controlled Trial With Safety Lead-in	256	Dec 2030
NCT04334785	Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer	186	May 2025

<i>Bone cancer</i>			
NCT05615545	Safety and Efficacy of Cryoablation in the Treatment of Advanced Bone and Soft Tissue Tumors: a Single-center Retrospective Study	30	Oct 2023

NCT: National Clinical Trial;

^a Denotes industry-sponsored or cosponsored trial.

Coding

Procedure codes on Medical Policy documents are included **only** as a general reference tool for each policy. **They may not be all-inclusive.**

The presence or absence of procedure, service, supply, or device codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. **Only the written coverage position in a Medical Policy should be used for such determinations.**

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member's benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT Codes	19105, 20983, 32994, 50250, 50541, 50542, 50593, 76940, 77013, 77022, 0581T
HCPCS Codes	None

*Current Procedural Terminology (CPT®) ©2023 American Medical Association: Chicago, IL.

References

1. Yanagisawa T, Mori K, Kawada T, et al. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. *Urol Oncol*. Jul 2022; 40(7):315-330. PMID 35562311
2. Uhlig J, Strauss A, Rucker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. *Eur Radiol*. Mar 2019; 29(3): 1293-1307. PMID 30255245
3. Klatte T, Shariat SF, Remzi M. Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. *J Urol*. May 2014; 191(5):1209-1217. PMID 24231845
4. Tang K, Yao W, Li H, et al. Laparoscopic renal cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal masses: a systematic review and meta-analysis of comparative studies. *J Laparoendosc Adv Surg Tech A*. Jun 2014; 24(6):403-410. PMID 24914926
5. Andrews JR, Atwell T, Schmit G, et al. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur Urol*. Aug 2019; 76(2):244-251. PMID 31060824

6. Rembeyo G, Correas JM, Jantzen R, et al. Percutaneous ablation versus robotic partial nephrectomy in the treatment of cT1b renal tumors: oncologic and functional outcomes of a propensity score-weighted analysis. *Clin Genitourin Cancer*. Apr 2020; 18(2):138-147. PMID 31982346
7. Yan S, Yang W, Zhu CM, et al. Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2-4 cm: A population-based study. *Medicine (Baltimore)*. May 2019; 98(21):e15610. PMID 31124938
8. Pecoraro A, Palumbo C, Knipper S, et al. Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer. *J Urol*. Dec 2019; 202(6):1120-1126. PMID 31347950
9. Cronan J, Dariushnia S, Bercu Z, et al. Systematic review of contemporary evidence for the management of T1 renal cell carcinoma: what IRs need to know for kidney cancer tumor boards. *Semin Intervent Radiol*. Aug 2019; 36(3):194-202. PMID 31435127
10. Morkos J, Porosnicu Rodriguez KA, Zhou A, et al. Percutaneous cryoablation for stage 1 renal cell carcinoma: outcomes from a 10-year prospective study and comparison with matched cohorts from the National Cancer Database. *Radiology*. Aug 2020; 296(2):452-459. PMID 32515677
11. Stacul F, Sachs C, Giudici F, et al. Cryoablation of renal tumors: long-term follow-up from a multicenter experience. *Abdom Radiol (NY)*. Apr 29 2021; 46(9):4476-4488. PMID 33912986
12. Lee SH, Choi WJ, Sung SW, et al. Endoscopic cryotherapy of lung and bronchial tumors: a systematic review. *Korean J Intern Med*. Jun 2011; 26(2):137-144. PMID 21716589
13. Niu L, Xu K, Mu F. Cryosurgery for lung cancer. *J Thorac Dis*. Aug 2012; 4(4):408-419. PMID 22934144
14. Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE). *J Thorac Oncol*. Jul 2020; 15(7):1200-1209. PMID 32151777
15. de Baere T, Tselikas L, Woodrum D, et al. Evaluating cryoablation of metastatic lung tumors in patients--safety and efficacy: the ECLIPSE trial--interim analysis at 1 year. *J Thorac Oncol*. Oct 2015; 10(10):1468-1474. PMID 26230972
16. Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. *J Vasc Interv Radiol*. Mar 2015; 26(3):312-319. PMID 25735518
17. Ratko TA, Vats V, Brock J, et al. Local nonsurgical therapies for stage I and symptomatic obstructive non-small-cell lung cancer (Report Number 13-EHC071-EF). Agency for Healthcare Research and Quality, Rockville (MD). Jun 2013. PMID 23865091
18. Maiwand MO, Asimakopoulos G. Cryosurgery for lung cancer: clinical results and technical aspects. *Technol Cancer Res Treat*. Apr 2004; 3(2):143-150. PMID 15059020
19. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. *Eur J Surg Oncol*. Dec 2010; 36(12):1149-1155. PMID 20889281
20. Simmons RM, Ballman KV, Cox C, et al. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (Alliance) Z1072. *Ann Surg Oncol*. 2016; 23(8):2438-2445. PMID 27221361
21. Niu L, Mu F, Zhang C, et al. Cryotherapy protocols for metastatic breast cancer after failure of radical surgery. *Cryobiology*. Aug 2013; 67(1):17-22. PMID 23619024

22. Manenti G, Perretta T, Gaspari E, et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. *Eur Radiol*. Nov 2011; 21(11):2344-2353. PMID 21681574
23. Pusztaszeri M, Vlastos G, Kinkel K, et al. Histopathological study of breast cancer and normal breast tissue after magnetic resonance-guided cryotherapy ablation. *Cryobiology*. Aug 2007; 55(1):44-51. PMID 17604016
24. Sabel MS, Kaufman CS, Whitworth P, et al. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. *Ann Surg Oncol*. May 2004; 11(5):542-529. PMID 15123465
25. Tanaka S. Cryosurgical treatment of advanced breast cancer. *Skin Cancer*. 1995; 10:9-18.
26. Pfeleiderer SO, Freesmeyer MG, Marx C, et al. Cryotherapy of breast cancer under ultrasound guidance: initial results and limitations. *Eur Radiol*. Dec 2002; 12(12):3009-3014. PMID 12439583
27. Suzuki Y. Cryosurgical treatment of advanced breast cancer and cryo immunological responses. *Skin Cancer*. 1995; 10:19-26.
28. Morin J, Traore A, Dionne G, et al. Magnetic resonance-guided percutaneous cryosurgery of breast carcinoma: technique and early clinical results. *Can J Surg*. Oct 2004; 47(5):347-351. PMID 15540687
29. Kaufman CS, Bachman B, Littrup PJ, et al. Office-based ultrasound-guided cryoablation of breast fibroadenomas. *Am J Surg*. Nov 2002; 184(5):394-400. PMID 12433600
30. Kaufman CS, Littrup PJ, Freeman-Gibb LA, et al. Office-based cryoablation of breast fibroadenomas: 12-month follow-up. *J Am Coll Surg*. Jun 2004; 198(6):914-923. PMID 15194073
31. Kaufman CS, Bachman B, Littrup PJ, et al. Cryoablation treatment of breast lesions with 12-month follow-up. *Am J Surg*. Oct 2004; 188(4):340-348. PMID 15474424
32. Littrup PJ, Freeman-Gibb L, Andea A, et al. Cryotherapy for breast fibroadenomas. *Radiology*. Jan 2005; 234(1):63-72. PMID 15550369
33. Kaufman CS, Littrup PJ, Freeman-Gibb L, et al. Office-based cryoablation of breast fibroadenomas with long-term follow-up. *Breast J*. Sep-Oct 2005; 11(5):344-350. PMID 16174156
34. Nurko J, Mabry CD, Whitworth P, et al. Interim results from the fibroadenoma cryoablation treatment registry. *Am J Surg*. Oct 2005; 190(4):647-651; discussion 651-652. PMID 16164941
35. Tao Z, Tang Y, Li B, et al. Safety and effectiveness of cryosurgery on advanced pancreatic cancer: a systematic review. *Pancreas*. Jul 2012; 41(5):809-811. PMID 22695092
36. Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. *World J Gastroenterol*. Mar 7 2014; 20(9):2267-2278. PMID 24605026
37. Li J, Chen X, Yang H, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. *Postgrad Med J*. Feb 2011; 87(1024):89-95. PMID 21131612
38. Xu KC, Niu LZ, Hu YZ, et al. A pilot study on combination of cryosurgery and (125) iodine seed implantation for treatment of locally advanced pancreatic cancer. *World J Gastroenterol*. Mar 14 2008; 14(10):1603-1611. PMID 18330956

39. Kovach SJ, Hendrickson RJ, Cappadona CR, et al. Cryoablation of unresectable pancreatic cancer. *Surgery*. Apr 2002; 131(4):463-464. PMID 11935137
40. Meller I, Weinbroum A, Bickels J, et al. Fifteen years of bone tumor cryosurgery: a single-center experience of 440 procedures and long-term follow-up. *Eur J Surg Oncol*. Aug 2008; 34(8):921-927. PMID 18158228
41. Callstrom MR, Dupuy DE, Solomon SB, et al. Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. *Cancer*. Mar 1 2013; 119(5):1033-1041. PMID 23065947
42. Jennings JW, Prologo JD, Garnon J, et al. Cryoablation for palliation of painful bone metastases: the MOTION multicenter study. *Radiol Imaging Cancer*. Mar 2021; 3(2): e200101. PMID 33817650
43. Purysko AS, Nikolaidis P, Dogra VS, et al. ACR Appropriateness criteria(R) post-treatment follow-up and active surveillance of clinically localized renal cell cancer. *J Am Coll Radiol*. Nov 2019; 16(11S):S399-S416. PMID 31685108
44. American College of Radiology (ACR). ACR Appropriateness Criteria: Post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. Updated 2021. Available at: <<https://acsearch.acr.org>> (accessed October 30, 2023).
45. Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. *J Urol*. Aug 2021; 206(2):199-208. PMID 34115547
46. NCCN – National Comprehensive Cancer Network® (NCCN). NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer (Version 4.2023). Available at: <<http://www.nccn.org>> (accessed on October 30, 2023).
47. NCCN – National Comprehensive Cancer Network® (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer (Version 5.2023). Available at: <<http://www.nccn.org>> (accessed on November 8, 2023).
48. NCCN – National Comprehensive Cancer Network® (NCCN). NCCN Clinical Practice Guidelines in Oncology. Adult Cancer Pain. (Version 2.2023). Available at: <<https://www.nccn.org>> (accessed November 8, 2023).

Centers for Medicare and Medicaid Services (CMS)

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <<https://www.cms.hhs.gov>>.

Policy History/Revision

Date	Description of Change
11/15/2024	Reviewed. No changes.
02/01/2024	Document updated with literature review. The following editorial change was made to coverage: Changed “patients” to “individuals”. Reference 1, 44 and 45 added; others updated.
05/15/2022	Document updated with literature review. The following change was made to Coverage: Palliative cryoablation may be medically necessary for intractable pain due to bone metastasis. Reference 39 added; others removed.
10/01/2020	Document updated with literature review. Coverage unchanged. References 20, 30, 44-47, 49, 50, 58, and 60-61 added/updated; others removed.
10/15/2019	Reviewed. No changes.
04/15/2018	Document updated with literature review. The following changes were made to Coverage: 1) Added “Cryosurgical ablation (cryoablation or cryosurgery) may be considered medically necessary to treat lung cancer when either of the following criteria is met: Patient has early-stage non-small cell lung cancer and is a poor candidate for surgery; OR Patient requires palliation for a central airway obstructing lesion; 2) Modified experimental, investigational and/or unproven listing for lung cancer to include “that does not meet the above criteria”. References 21-23, 29, 41, and 53 added, reference list updated, and none removed.
10/15/2017	Reviewed. No changes.
02/15/2017	Document updated with literature review. The following renal cell carcinoma medically necessary coverage statement has been changed to, “Cryosurgical ablation (cryoablation or cryosurgery), whether open, percutaneous or laparoscopic, may be considered medically necessary to treat localized renal cell carcinoma (RCC) that is no more than 4 centimeters in size.” The following renal cell carcinoma experimental, investigational and/or unproven coverage statement has been changed to, “Cryosurgical ablation (cryoablation or cryosurgery), whether open, percutaneous or laparoscopic, is considered experimental, investigational and/or unproven for all of the following” indications listed in this leading coverage statement.
11/01/2015	Reviewed. No changes.
07/01/2014	Document updated. Coverage is unchanged; however the Coverage of cryoablation of renal cell carcinoma (RCC) was moved to this policy from SUR710.017 (Radiofrequency Ablation [RFA] and Cryoablation of Renal Cell Carcinoma [RCC]) and SUR710.017 was deleted. Therefore, the following statements were moved to Coverage in this policy: 1) Cryoablation of RCC may be considered medically necessary when detailed listed criteria are met. Cryoablation of RCC is considered experimental, investigational and/or unproven when criteria are not met. Rationale and References were also updated to include RCC. Title changed from Cryosurgical Ablation of

	Miscellaneous Solid Tumors Other Than Renal, Liver, Prostate, or Dermatologic Tumors.
06/15/2013	Document updated with literature review. The following was changed: cryosurgical ablation (cryoablation or cryosurgery) may be considered medically necessary for the treatment of breast fibroadenoma when ALL of the following criteria have been met: the lesion is sonographically visible; AND the diagnosis is histologically confirmed; AND the lesion is less than 2.5 cm in it largest diameter. Otherwise, coverage remains unchanged.
03/15/2013	Document updated with literature review. The following: Cryoablation is considered experimental, investigational and unproven for treatment of benign or malignant tumors of the pancreas; lung; bone; or other solid tumors outside of the kidneys, liver or prostate. Title changed from Cryosurgical Ablation for Breast Lesions. Rationale significantly revised. References rearranged and numbered. CPT/HCPCS code(s) updated.
09/01/2010	Document updated with literature review. Coverage unchanged.
07/15/2008	Revised/updated entire document
02/27/2004	New medical document